Vendor Intelligence Report: Peptide Sciences

Published 3 Jul 2026. 27-page investigative report on who is behind Peptide Sciences: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptide Sciences is no longer an active-vendor review. The brand announced it stopped trading on 6 Mar 2026, and the original site now carries an unusually explicit warning that it has not rebranded. Finnrick's buyer posture is categorical: any active checkout, reseller, social offer or discount page claiming current Peptide Sciences supply should be treated as fraudulent unless a future independently verified relaunch exists.

The live hazard is a post-shutdown P-Sciences lookalike. The report documents a domain registered weeks after closure, a Fort Lauderdale virtual-office address, cryptocurrency checkout, Florida Secretary of State no-match searches for the displayed names, and complaint records alleging crypto or Zelle payment fraud. The original domain's anti-successor notice makes the name collision more serious, not less.

Across 130 Finnrick lab tests, Peptide Sciences shows 78 pass and 52 fail, an overall pass rate of 60%. The average hides a split catalog: Semaglutide and GHK-Cu are the stronger legacy signals, while CJC-1295 is the clearest failure and Retatrutide is too uneven to trust by label. Some ratings lose standing when stricter scoring is applied, so the product-level appendix matters for authenticated pre-shutdown stock only; it is not a green light to buy today.

The investigation also separates rumor from proof: QR Peptides did not resolve as an active storefront, peptides.gg showed separate contact infrastructure, and the promotion scan found stale coupon/code funnels that can keep a closed brand looking alive. The unresolved corporate trail around the legacy operator is treated as a limit, not inflated into certainty.

Inside the full report:

  • Original peptidesciences.com shutdown capture and anti-successor warning analysis
  • WHOIS/RDAP, DNS notes, storefront captures and payment-page evidence for the P-Sciences lookalike
  • Florida Secretary of State no-match exhibits, with Delaware and Wyoming access limits separated from confirmed negatives
  • Per-product pass/fail rates, methodology-divergence charts and Appendix A lab data for all 10 Finnrick-tested products
  • QR Peptides DNS and Hostinger staging checks, plus peptides.gg separation analysis
  • X/web affiliate and coupon scan, including code-promotion artifacts and disclosure review

Risk assessment

  • Current-purchase fraud and impersonation risk — high: Peptide Sciences stopped trading on 6 Mar 2026; peptidesciencesinc.com is a post-shutdown lookalike with crypto payments, a virtual address, no Florida registry match and consumer fraud complaints.
  • Product-specific quality failure risk for Peptide Sciences-labeled stock — high: Finnrick records 130 tests with 78 pass and 52 fail; highest-concern products include CJC-1295 at 16.05%, Tesamorelin at 39.72%, Retatrutide at 56.09% and Melanotan II at 54.18%.
  • Corporate and channel-verification opacity concern — medium: The materials show no signed COA portal, authorized-reseller list or lot-authentication system; the impersonator has no Florida registry match and Delaware/Wyoming checks did not produce usable confirming results.
  • Affiliate-promotion and stale-coupon risk — medium: The X/web scan found 12 promoter or coupon records, nine carrying a code or link with no clear disclosure, creating stale funnels around a closed and impersonated brand.